ArticleSignal transduction and targeted therapy2025
Single-cell transcriptomic analysis reveals gut microbiota-immunotherapy synergy through modulating tumor microenvironment.
Abstract read
In one paragraph
Article in Signal transduction and targeted therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Microbiome and Response to Therapy in Triple Negative Breast Cancer: A Systematic Review.Oncology research · 2026Pooled it
- Global research trends in gut microbiota and cellular senescence: a bibliometric and visual analysis from 2015 to 2025.Frontiers in microbiology · 2025Pooled it
- Fecal microbiota transplantation for advanced non-small cell lung cancer with secondary PD-1 resistance efficacy prognostic factors and microbiome diversity analysis.Journal of translational medicine · 2026Trial
- A machine-learning informed circulating microbial DNA signature for early diagnosis of esophageal adenocarcinoma.Gut microbes · 2026Article
- Mechanisms of traditional Chinese medicine in enhancing the efficacy and reducing the toxicity of immune checkpoint inhibitorsJournal of enzyme inhibition and medicinal chemistry · 2026Review
- Article
- Cell Membrane-Engineered FePDA Nanoparticles Integrate Ferroptosis and Antitumor Immunity.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Harnessing the gut microbiome for improved immune checkpoint inhibition in colorectal cancer immunotherapy: a narrative Review.Clinical and experimental medicine · 2026Review
- Spatial single-cell landscape of tumor-associated macrophages and their crosstalk with the tumor microenvironment.Cell discovery · 2026Article
- The gut-liver/bile axis: Gut microbiota and bacterial extracellular vesicles remodeling hepatobiliary pathogenesis.iScience · 2026Review
- Bidirectional Interactions Between Immune Regulation and the Insulin-like Growth Factor Axis in Colorectal Cancer.International journal of molecular sciences · 2026Review
- Harnessing NIR-II-responsive Rh single-atom nanozymes for photothermal-catalytic immunomodulation and eradication of drug-resistant biofilms in deep tissues.Materials today. Bio · 2026Article
- Butyrate-producing Eubacterium rectale inhibits gastric carcinogenesis and augments the efficacy of immunotherapy.Journal of translational medicine · 2026Article
- Bacterial colonization of tumors drives immune activation and checkpoint blockade efficacy.Scientific reports · 2026Article
- Targeting macrophage-derived SPP1 enhances CD8 T cell infiltration via ROS-DNA fragment/cGAS-STING/STAT1-mediated CXCL9/10 in tumor microenvironment.Journal for immunotherapy of cancer · 2026Article
- CA9+ cancer-associated fibroblasts cooperate with SPP1+ tumor-associated macrophages driving immune resistance in triple-negative breast cancer.Cellular and molecular life sciences : CMLS · 2026Article
- A pan-cancer single cell landscape reveals heterogeneity and functional diversity of double-negative T cells.Molecular cancer · 2026Article
- Identification and Validation of Mitophagy-Related Biomarkers in Colorectal Cancer: An Integrated Analysis of Single-Cell Transcriptome and Mendelian Randomization.Genetics research · 2026Article
- Gut metabolites: key factors in the cross-talk between the gut microbiota and tumor immunotherapy.Frontiers in immunology · 2026Review
- Microbial and metabolic signatures of humanized microbiome mice associate withFrontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Minyuan Cao *Department of Laboratory Medicine/Research Centre of Clinical Laboratory Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Yun Deng *State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Qing Hao *State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Huayun Yan *State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Quan-Lin Wang *Department of Clinical Pharmacology, Xiangya Hospital, Central Laboratory of Hunan Cancer Hospital, Central South University, Changsha, China.
Chunyan DongState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Jing WuState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Yajiao HeState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Li-Bin HuangDivision of Gastrointestinal Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China.
Xuyang XiaDepartment of Laboratory Medicine/Research Centre of Clinical Laboratory Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Yongchao GaoDepartment of Clinical Pharmacology, Xiangya Hospital, Central Laboratory of Hunan Cancer Hospital, Central South University, Changsha, China.
Hai-Ning ChenColorectal Cancer Center, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China.ORCID 0000-0003-0104-8498
Wei-Han ZhangGastric Cancer Center, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China.
Yan-Jing ZhangCore Facilities, West China Hospital, Sichuan University, Chengdu, China.
Xiaozhen ZhuoDepartment of Cardiology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Lunzhi DaiState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.ORCID 0000-0002-3003-8910
Hongbo HuState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.ORCID 0000-0002-8177-7641
Yong PengState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.ORCID 0000-0002-1181-3467
Feng ZhangCenter for Precision Medicine, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, China.
Zhaoqian LiuDepartment of Clinical Pharmacology, Xiangya Hospital, Central Laboratory of Hunan Cancer Hospital, Central South University, Changsha, China.ORCID 0000-0003-0428-3928
Weihua HuangDepartment of Clinical Pharmacology, Xiangya Hospital, Central Laboratory of Hunan Cancer Hospital, Central South University, Changsha, China.
Huiyuan ZhangState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.ORCID 0000-0002-1532-2462
Li YangState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Yang ShuState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Wei ZhangDepartment of Clinical Pharmacology, Xiangya Hospital, Central Laboratory of Hunan Cancer Hospital, Central South University, Changsha, China. csuzhangwei@csu.edu.cn.ORCID 0000-0002-6190-3129
Yan ZhangLung Cancer Center/Lung Cancer Institute, Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu, China. zhang.yan@scu.edu.cn.
Heng XuDepartment of Laboratory Medicine/Research Centre of Clinical Laboratory Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China. xuheng81916@scu.edu.cn.ORCID 0000-0002-7748-2621
Funding
National Natural Science Foundation of China (National Science Foundation of China) 82273445
Abstract
The gut microbiota crucially regulates the efficacy of immune checkpoint inhibitor (ICI) based immunotherapy, but the underlying mechanisms remain unclear at the single-cell resolution. Using single-cell RNA sequencing and subsequent validations, we investigate gut microbiota-ICI synergy by profiling the tumor microenvironment (TME) and elucidating critical cellular interactions in mouse models. Our findings reveal that intact gut microbiota combined with ICIs may synergistically increase the proportions of CD8
Indexed as
Gastrointestinal MicrobiomeImmune Checkpoint InhibitorsImmunotherapyNeoplasmsSingle-Cell AnalysisTumor MicroenvironmentAnimalsCD8-Positive T-LymphocytesGene Expression ProfilingHumansMacrophagesMiceMice, KnockoutTranscriptomeImmune Checkpoint Inhibitors
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.